ArticleHeliyon2024

CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia.

Jie Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.